Search

Your search keyword '"Simon L. Collinson"' showing total 2 results
Start Over Author "Simon L. Collinson" Publisher bmj publishing group
2 results on '"Simon L. Collinson"'

1. Additive effect of cerebral atrophy on cognition in dementia-free elderly with cerebrovascular disease

Author

Tien Yin Wong, Xin Xu, April Phua, Simon L Collinson, Saima Hilal, Mohammad Kamran Ikram, Ching Yu Cheng, Narayanaswamy Venketasubramanian, and Christopher Chen

Subjects
Neurology. Diseases of the nervous system, RC346-429
Abstract

Objective To explore the additive effect of neurodegenerative diseases, measured by atrophy, on neurocognitive function in Asian dementia-free elderly with cerebrovascular disease (CeVD).Methods The present study employed a cross-sectional design and was conducted between 2010 and 2015 among community-dwelling elderly participants recruited into the study. Eligible participants were evaluated with an extensive neuropsychological battery and neuroimaging. The weighted CeVD burden scale comprising markers of both small- and large-vessel diseases was applied, with a score of ≥2, indicating significant CeVD burden. Cortical atrophy (CA) and medial temporal atrophy (MTA) were graded using the global cortical atrophy scale and Schelten’s scale, respectively. Global and domain-specific (attention, executive function, language, visuomotor speed, visuoconstruction, visual memory, and verbal memory) neurocognitive performance was measured using a locally validated neuropsychological battery (Vascular Dementia Battery, VDB).Results A total of 819 dementia-free participants were included in the analysis. Among none-mild CeVD subjects, there was no significant difference in the global cognitive performance across atrophy groups (no atrophy, CA, and CA+MTA). However, in moderate-severe CeVD subjects, CA+MTA showed significantly worse global cognitive performance compared with those with CA alone (mean difference=−0.35, 95% CI −0.60 to −0.11, p=0.002) and those without atrophy (mean difference=−0.46, 95% CI −0.74 to −0.19, p

Published
2019
Full Text
View/download PDF

2. Cognitive screening improves the predictive value of stroke severity scores for functional outcome 3–6 months after mild stroke and transient ischaemic attack: an observational study

Author

Simon L. Collinson, Christopher Chen, Perminder S. Sachdev, John D. Crawford, Yanhong Dong, Vivek Sharma, Bernard Poon-Lap Chan, Melissa J. Slavin, and Narayanaswamy Venketasubramanian

Subjects
Geriatrics, medicine.medical_specialty, Neurology, business.industry, Research, Montreal Cognitive Assessment, General Medicine, REHABILITATION MEDICINE, medicine.disease, Predictive value, nervous system diseases, GERIATRIC MEDICINE, Modified Rankin Scale, Internal medicine, medicine, Physical therapy, Observational study, cardiovascular diseases, business, Stroke, Neurocognitive
Abstract

Objectives To investigate the prognostic value of the neurocognitive status measured by screening instruments, the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE), individually and in combination with the stroke severity scale, the National Institute of Health Stroke Scale (NIHSS), obtained at the subacute stroke phase or the baseline (≤2 weeks), for functional outcome 3–6 months later. Design Prospective observational study. Setting Tertiary stroke neurology service. Participants 400 patients with a recent ischaemic stroke or transient ischaemic attack (TIA) received NIHSS, MoCA and MMSE at baseline and were followed up 3–6 months later. Primary outcome measures At 3–6 months following the index event, functional outcome was measured by the modified Rankin Scale (mRS) scores. Results Most patients (79.8%) had a mild ischaemic stroke and less disability (median NIHSS=2, median mRS=2 and median premorbid mRS=0), while a minority of patients had TIA (20.3%). Baseline NIHSS, MMSE and MoCA scores individually predicted mRS scores at 3–6 months, with NIHSS being the strongest predictor (NIHSS: R2 change=0.043, p2), baseline MoCA and MMSE had a significant and moderately large incremental predictive value to the baseline NIHSS for mRS scores at 3–6 months (MMSE: R2 changes=0.021, p=0.010; MoCA: R2 changes=0.017, p=0.021). Conclusions Cognitive screening at the subacute stroke phase can predict functional outcome independently and improve the predictive value of stroke severity scores for functional outcome 3–6 months later, particularly in patients with more severe stroke.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results